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’ INTRODUCTION
White adipose tissue (WAT) is one of the major contributors
to energy homeostasis in humans. Since lipids contribute 70% of
WAT, this tissue is also a major reservoir for lipophilic con-
taminants, which might interfere with the diﬀerentiation, meta-
bolism, and secretory functions of adipocytes.1 Exposure to an
increasing number of chemicals is suspected to play a role in the
development of the obesity epidemic, and the environmental
obesogen concept was introduced recently.2 In this context,
some environmental pollutants are of particular concern because
they interfere with nuclear receptors controlling the expression
of genes involved in energy homeostasis such as those encoding
the peroxisome proliferator-activated receptors (PPARs). PPARγ,
the dominant PPAR isoform in humanWAT, is an ideal target for
these so-calledmetabolic disruptors, since it regulates lipid storage,
induces adipocyte diﬀerentiation and survival, and contributes to
control insulin sensitivity.3
Phthalate esters are industrial chemicals used as plasticizers to
improve the pliability of PVC products. Di(2-ethylhexyl) phtha-
late (DEHP), the most widely used of the phthalate esters, is
found in ﬂexible plastics of a wide variety of common products
such as medical devices, cosmetics, industrial paints, solvents, or
food packaging. DEHP is not covalently bound to its matrix and
its propensity to leak can lead to high levels of human exposure.
After ingestion, intestinal lipases convert DEHP into its monoester
derivative monoethylhexyl-phthalate (MEHP), which is then
preferentially absorbed.4 MEHP can also originate from the
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ABSTRACT: Adipose tissue is a major storage site for lipophilic environmental
contaminants. The environmental metabolic disruptor hypothesis postulates that
some pollutants can promote obesity or metabolic disorders by activating nuclear
receptors involved in the control of energetic homeostasis. In this context, mono-
ethylhexyl phthalate (MEHP) is of particular concern since it was shown to activate the
peroxisome proliferator-activated receptor γ (PPARγ) in 3T3-L1 murine preadipo-
cytes. In the present work, we used an untargeted, combined transcriptomic-1HNMR-
based metabonomic approach to describe the overall eﬀect of MEHP on primary
cultures of human subcutaneous adipocytes diﬀerentiated in vitro. MEHP stimulated
rapidly and selectively the expression of genes involved in glyceroneogenesis,
enhanced the expression of the cytosolic phosphoenolpyruvate carboxykinase, and
reduced fatty acid release. These results demonstrate that MEHP increased glycer-
oneogenesis and fatty acid reesteriﬁcation in human adipocytes. A longer treatment
with MEHP induced the expression of genes involved in triglycerides uptake, synthesis, and storage; decreased intracellular lactate,
glutamine, and other amino acids; increased aspartate and NAD, and resulted in a global increase in triglycerides. Altogether, these
results indicate that MEHP promoted the diﬀerentiation of human preadipocytes to adipocytes. These mechanisms might
contribute to the suspected obesogenic eﬀect of MEHP.
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conversion of DEHP by plasmatic or hepatic lipases. In vitro
trans-activation studies have shown that MEHP can activate the
three isoforms of PPAR receptors in human and murine cell
lines.5 Furthermore, it has also been demonstrated that, in the
murine 3T3-L1 preadipocyte cell line, MEHP activated PPARγ
and promoted adipose cell diﬀerentiation (adipogenesis).6 Con-
sequently, MEHP has been considered as a potential obesogen
and metabolic disruptor.7 However, the eﬀects of MEHP on
human WAT remain unknown.
Understanding the eﬀects of pollutants in humans raises
complex challenges. Extrapolation from animal models is diﬃcult
and depends on the conservation of the underlying molecular
mechanisms of action between species. Regarding PPAR activa-
tors in general, and for DEHP and MEHP in particular, these
molecular mechanisms have been shown to diﬀer greatly
between rodentmodels and humans. In rodents, PPAR activators
induce sustained hepatic peroxisome proliferation mediated by
PPARα, which is likely to inﬂuence the metabolic phenotype of
these animals.8 This phenomenon does not occur in humans.
Mice treated with DEHP are protected fromweight gain induced
by a high fat diet, but this phenomenon is reversed in mice
expressing the human PPARα.9 These results clearly demon-
strate that the eﬀects of DEHP on WAT can be species-speciﬁc
and emphasize the importance of using human models to
investigate its mechanisms of action.
In vivo, human subcutaneousWAT is constituted of amajority
of mature adipocytes representingmore than 50% of the total cell
count, surrounded by other cell types constituting the stroma-
vascular fraction, among which ﬁbroblasts and preadipocytes.10,11
In the present work, we investigated the eﬀects of MEHP on
primary cultures of human adipocytes, whichwere diﬀerentiated in
vitro for 11 days. The cultures contained about 30% of preadipo-
cytes and a majority of mature adipocytes. The perturbations
induced by MEHP in human adipocytes diﬀerentiated in vitro
were described using an untargeted systems biology approach
combining transcriptomics and 1H NMR-based metabonomics at
several time points. We found evidence that MEHP activated two
diﬀerentmetabolic pathways in human adipocytes diﬀerentiated in
vitro, namely, glyceroneogenesis and adipocyte diﬀerentiation,
thereby increasing triglyceride content.
’EXPERIMENTAL PROCEDURES
Cell Culture
Primary cultures of human preadipocytes were provided by
Promocell (www.promocell.com) and originated from the sub-
cutaneous adipose tissue of ﬁve healthy women, aged 36( 5 and
with a BMI < 28 kg/m2. Preadipocyte growth and in vitro
diﬀerentiation into adipocytes were conducted according to
the provider’s recommendations. Brieﬂy, preadipocytes were
grown in Promocell Preadipocyte Growth Medium containing
5% fetal calf serum, 1 μg/mL hydrocortisone, 10 ng/mL human
recombinant growth factor, and 4 μL/mL heparin, until con-
ﬂuence (day 0). Diﬀerentiation into adipocytes was then induced
using Promocell Preadipocyte Diﬀerentiation Medium contain-
ing 3 μg/mL ciglitazone, 8 μg/mL biotin, 400 ng/mL dexa-
methasone, 44 μg/mL 3-isobutyl-1-methylxanthine, 0.5 μg/mL
insulin, and 9 ng/mL thyroxine for 3 days (until day 3). Dif-
ferentiation was pursued for 8 days in Promocell Adipocyte
Nutrition Medium containing 3% fetal calf serum, 8 μg/mL
biotin, 400 ng/mL dexamethasone, and 0.5 μg/mL insulin (until
day 11). On day 11, about 70% of the cells were diﬀerentiated
into adipocytes and about 30% remained undiﬀerentiated.
Cell Treatment
On day 11, the cells were treated with 100 μM MEHP
(Interchim, Montluc-on, France) dissolved in DMSO (ﬁnal
concentration 0.1%). This concentration was chosen based on
previous ﬁndings of the literature because it induced maximal
activation of the human PPARγ.5 To minimize variations due to
cell culture conditions, cells from the ﬁve primary cultures were
grown and treated in parallel for the transcriptomic and meta-
bonomic analyses. Each primary culture was divided between
two T75 ﬂasks: one was used for RNA extraction and subsequent
transcriptomic proﬁling and the other for cell pellet recovery and
subsequent metabolic proﬁling. For all other complementary
experiments, the same ﬁve primary cultures were used.
Transcriptomics and Data Analysis
At 24 h of treatment, total RNA was prepared as previously
described.12 RNA quality was veriﬁed on an Agilent Bioanalyzeur
2100. Hybridization, cleaning, and scanning of Human Gene 1.0
ST microarrays were performed according to the manufacturer’s
instructions (Aﬀymetrix Inc., www.aﬀymetrix.com) on the geno-
mic platform of the Cochin Institute.
Data were normalized using Robust Multi-Array Average
expression measure (RMA) Bioconductor package implemented
on R (www.bioconductor.org). Log2 normalized data were
analyzed using the signiﬁcant analysis of microarray (SAM)
paired test (http://www-stat.stanford.edu/∼tibs/SAM/).13 SAM
gives a list of signiﬁcantly regulated genes and estimates the false
positive rate. For the data presented in this study, the false discovery
rate was limited to 5%.
Gene ontology analyses were conducted using the bioinfor-
matics tool DAVID (http://david.abcc.ncifcrf.gov:8080/). A
combination of an enrichment score of 2 and a corrected p value
< 0.05 was considered signiﬁcant. We also used the link
between DAVID and the KEGG metabolic database (http://
www.genome.jp/kegg/pathway.html) and selected the pathways
that had a p value < 0.05. For more details on DAVID, see ref 14.
1H NMR Metabonomics and Data Analysis
At 24 or 48 h of treatment, cells were trypsinized at room
temperature andwashed twice in phosphate buﬀer saline before the
cell pellet was frozen at 80 C. Polar and lipophilic metabolites
were extracted from the cell pellets using a chloroform/methanol/
water (2:1:3) mixture as described previously.15 The supernatant
containing the aqueous phasewas taken, freeze-dried, and dissolved
in 50 μL of phosphate buﬀer 0.2 M (pH 7.4) in D2O plus 0.001%
TSP and transferred to microcapillary tubes. The inferior chloro-
form phase was taken, dried, and dissolved in 100 μL of CDCL3
plus 0.01% TMS and transferred to microcapillary tubes.
All spectra were acquired on a Bruker Avance 600 MHz
spectrometer (Bruker Analytische GmbH, Rheinstetten,
Germany), operating at 600.13 MHz, with a spectral width of
12 000 Hz. For aqueous phases, spectra were acquired with a
standard one-dimensional sequence [relaxation delay-90-t1-
90-tm-90-acquire free induction decay], with a water presa-
turation applied for 2 s and a mixing time (tm) of 100 ms and a
90 pulse length of 10 μs, using 512 scans and 64K data points.
For organic phases, spectra were acquired with a standard 1D
sequence with a relaxation delay of 3 s and a 90 pulse length of
3μs, using 16 scans and 32Kdata points. The FIDsweremultiplied
by an exponential function corresponding to 0.3 Hz line
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broadening. All spectra were manually phased, baseline cor-
rected, and calibrated to TSP (δ0.00). Metabolites were assigned
using previously published data16,17 and additional two-dimen-
sional NMR experiments on selected samples.
To eliminate the variability in water resonance presaturation,
the chemical shift region between δ4.66 and 4.88 was removed
from all spectra prior to statistical analysis. As previously
described,18 all data were analyzed on full-resolution spectra
(33 600 data points), and aqueous phase spectra were normal-
ized to the total peak area. Despite the use of phosphate buﬀer
(pH 7.2), many aqueous phase spectra still displayed subtle
shifts. These diﬀerences were corrected using an alignment
function.19 For organic phase spectra, the peak area for each
signal was integrated (13 peaks). The resulting peak area proﬁle
was normalized to a constant sum of the peak area for the two
cholesterol signals (δ0.9 and 1.1).
1H NMR proﬁles from aqueous phases were mean-centered
and scaled to unit variance, and 1H NMR proﬁles from organic
phases were mean centered prior to analysis using Matlab
software version R2009a (The MathWorks Inc.). 1H NMR
proﬁles were analyzed using orthogonal projection on latent
structure-discriminant analysis (O-PLS-DA), where 1H NMR
data were used as independent variables (Xmatrix) and regressed
against a dummymatrix (Ymatrix) indicating the class of samples
(DMSO orMEHP).20 All O-PLS-derived models were evaluated
for goodness of prediction (Q2Y value) using 5-fold cross-
validation. The reliability of each model was established using a
permutation test of the Y vector (1000 permutations) in order to
determine a p value for each Q2Y, as previously described.21 To
identify metabolites responsible for discrimination between
MEHP- and DMSO-treated cells, the O-PLS-DA correlation
coeﬃcients (r2) were calculated for each variable and back-scaled
into a spectral domain, so that the shape of NMR spectra and
the sign of the coeﬃcients were preserved.18 The weights of
the variables were color-coded, according to the square of the
O-PLS-DA correlation coeﬃcients. Correlation coeﬃcients ex-
tracted from signiﬁcant models were ﬁltered so that only
signiﬁcant correlations above the threshold deﬁned by Pearson’s
critical correlation coeﬃcient (P < 0.05; r2 = 0.38 when n = 10)
were considered signiﬁcant.
Determination of Intracellular Triglycerides
Human preadipocytes from the same ﬁve women were diﬀer-
entiated in vitro for 11 days before treatment with 100 μMMEHP
or 0.1% DMSO for 24 or 48 h. At day 0, day 3, day 6, day 9, and
day 11 of diﬀerentiation, as well as after 24 and 48 h of treatment
with MEHP or DMSO, cells were trypsinized, washed twice with
PBS, suspended in 100 μL of PBS, and frozen at 80 C.
Intracellular triglycerides were measured using the “TG enzy-
matic PAP 150” kit from Biomerieux (Marcy l’Etoile, France)
and normalized to protein content determined using the
bicinchonic acid method (Pierce biotechnology, Rockford, IL).
Each measurement was performed in triplicate.
Real Time Quantitative PCR (RT-QPCR)
Human preadipocytes from the same ﬁve women were
diﬀerentiated in vitro for 11 days before treatment with MEHP
100 μM or DMSO 0.1% for 4, 8, or 24 h. Total RNA extraction
was performed as for the transcriptomic study. Reverse transcrip-
tion, RT-QPCR and data analysis were performed as previously
described12 using primers described in Supplemental Table 1,
Supporting Information and RPL13A as housekeeping gene.
Western Blot
Human preadipocytes from the same ﬁve women were diﬀer-
entiated in vitro for 11 days before treatment with 100 μMMEHP
or 0.1% DMSO for 18 h. Proteins were extracted using RIPA
buﬀer according to the manufacturer’s instructions (Santa-Cruz
Biotechnology, Heidelberg, Germany). Cell lysates were centri-
fuged for 15 min at 14000g and 4 C to retrieve the cytosol.
Western blotting with anti-PEPCK-C was conducted as de-
scribed previously,22 using actin as an internal standard to ensure
the quantity of loaded protein.
Determination of Nonesterified Fatty Acids (NEFA) Released
in Culture Medium
Human preadipocytes from the same ﬁve women were dif-
ferentiated in vitro for 11 days before treatment with 100 μM
MEHP or 0.1% DMSO for 18 h. They were fasted for 3 h in
DMEM without glucose, containing 3% (w/v) fatty acid-free
bovine serum albumin, and then transferred in a Krebs Ringer
Bicarbonate buﬀer containing 5 mM pyruvate for 2 h. This
medium was collected and NEFA was measured using a colori-
metric method with the Free Fatty Acids Half-Micro Test kit
from Roche Diagnostics GmbH (Mannheim, Germany). Each
measurement was performed in triplicate.
’RESULTS
Transcriptomic Effects of MEHP on Human Adipocytes
To assess the eﬀects of MEHP on human WAT, primary
cultures of subcutaneous preadipocytes (n = 5) were diﬀeren-
tiated in vitro into adipocytes for 11 days and treated withMEHP
(100 μM) or with DMSO (vehicle, 0.1% ﬁnal). An untargeted
global proﬁling approach combining transcriptomics and 1H
NMR-based metabonomics was used, starting with transcrip-
tomic proﬁling at 24 h of treatment. Principal component
analysis (PCA) conducted on the entire transcriptomic proﬁle
clearly separated MEHP and DMSO-treated human adipocytes,
indicating that MEHP strongly modiﬁed gene expression
(Figure 1A). Using a paired SAM test, we selected 227 genes
signiﬁcantly diﬀerentially regulated between MEHP- and
DMSO-treated adipocytes: 142 upregulated and 85 downregu-
lated (Supplemental Table 2, Supporting Information). The
biological pathways modulated byMEHP were then investigated
using gene ontology analyses of the 142 upregulated transcripts
or of the 85 downregulated transcripts in theDAVID (Figure 1B)
and KEGG databases (Figure 1C). The same gene ontology
analysis using all 227 genes together identiﬁed the same biolo-
gical pathways and is therefore not reported here.
The analysis of upregulated transcripts ﬁrst showed that the
most signiﬁcantly activated biological pathway was the “PPAR
signaling pathway” which contained 12 genes (p = 3  107,
Supplemental Table 3, Supporting Information). This result
indicated thatMEHP probably activated PPARγ, themost highly
expressed PPAR isoform in WAT. MEHP treatment also
enhanced metabolic processes involved in lipid metabolism, as
illustrated by the following signiﬁcant terms in the gene ontology
analyses: “Carboxylic acid metabolic process” (p = 2.7  104),
“Fatty acid biosynthesis” (p = 2  103), “Fatty acid binding”
(p = 1.0  102), “Polyunsaturated fatty acid biosynthesis”
(p = 1.7  102) and “Fatty acid metabolism” (p = 1.9 102).
Finally, the analysis of down-regulated transcripts showed
that MEHP disrupted genes involved in cell shape and in
cellenvironment interactions, as indicated by the terms
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“Glycoprotein/secreted” (p = 5.7 106), “Extracellular matrix”
(p = 8.9 103), and “Regulation of the actin cytoskeleton” (p =
5  102).
1H NMR Based Metabolic Profiling of MEHP-Treated Human
Adipocytes
The metabolic disruptions induced by MEHP in human
adipocytes were evaluated in the same cell cultures (n = 5) at
24 and 48 h of treatment using 1H NMR proﬁling on both the
organic and the aqueous fractions of cell extracts. Metabolic
alterations induced byMEHP treatment were ﬁrst investigated in
the polar extracts of human adipocytes (Figure 2A). To assess the
diﬀerences between the metabolic proﬁles of MEHP- versus
DMSO-treated human adipocytes, we constructed O-PLS-DA
models at 24 and 48 h as described in Experimental Procedures.
The metabolic proﬁles of MEHP-treated adipocytes diﬀered
markedly from those of DMSO-treated cells, at both 24 h
(parameters of the O-PLS-DA performed with one predictive
component and one orthogonal component: R2X = 0.63, R2Y =
0.87, Q2Y = 0.73, p = 0.001, Supplemental Figure 1, Supporting
Information) and 48 h of treatment (parameters of the O-PLS-
DA performed with one predictive component and one ortho-
gonal component: R2X = 0.65, R2Y = 0.94,Q2Y = 0.73, p = 0.009;
Figure 2B). The metabolites responsible for this discrimina-
tion were determined by computing their correlation coeﬃ-
cient (r2) derived from the O-PLS-DA models (Supplementary
Table 4, Supporting Information). At both time points, MEHP-
treated adipocytes displayed lower intracellular levels of
lactate and of several amino acids, including valine, glutamine,
phenylalanine, and tyrosine, as well as higher levels of aspartate.
MEHP treatment also inﬂuenced the level of metabolites
involved in phospholipid metabolism, as indicated by higher
levels of phosphoethanolamine and choline, and lower levels of
glycerophosphocholine in MEHP-treated adipocytes. Finally,
NAD+ and creatine levels were increased in MEHP-treated
adipocytes.
In the apolar organic cell extracts, signals from various
lipophilic molecules such as cholesterol, glycerol linked to
phospholipids and/or to triglycerides and fatty acids were
detected (Figure 2C). As most of these signals derived from
fatty acids (either free or esteriﬁed in triglycerides), the conven-
tional method of normalization, dividing each spectral data point
by the total spectral area, was not adequate. For example, a global
increase of triglyceride content in one group would be missed
using this method. Therefore, 1H NMR peaks were integrated
and normalized to cholesterol signals (δ0.68 and δ1.01). This
normalization resulted in a simpliﬁed data matrix containing 13
variables. At 24 h of treatment, no diﬀerence was observed
between MEHP- and DMSO-treated human adipocytes (Q2Y
< 0, data not shown). At 48 h of treatment, signiﬁcant diﬀerences
were observed between the organic metabolic proﬁles of MEHP-
treated compared to DMSO-treated human adipocytes
(parameters of the O-PLS-DA performed with one predictive
component and two orthogonal components: R2X = 0.93, R2Y =
0.98,Q2Y = 0.68, p = 0.03). The discrimination between MEHP-
andDMSO-treated human adipocytes wasmainly due to a higher
level of the protons involved in fatty acid double bonds (δ5.35,
signal J, r2 = 0.41, p = 0.046) in MEHP-treated adipocytes
(Figure 2D). Two of the three glycerol signals showed increases
of borderline signiﬁcance in MEHP-treated adipocytes (δ5.28,
signal I, r2 = 0.26, p = 0.13 and δ4.33, signal H, r2 = 0.29, p = 0.1).
Assessment of Intracellular Triglyceride Content in Human
Adipocytes
The previous untargeted transcriptomic and metabonomic
observations demonstrated that MEHP signiﬁcantly disrupted
Figure 1. Transcriptomic eﬀects of MEHP on human adipocytes. Human preadipocytes (n = 5) were diﬀerentiated in vitro into adipocytes for 11 days
and then treated with MEHP (100 μM) or DMSO (0.1%, vehicle) for 24 h. (A) PCA analysis was conducted using expression data from the entire
microarray (32 322 probesets). Black: DMSO, red: MEHP. (B, C) Gene ontology analyses were conducted on the 142 signiﬁcantly upregulated and on
the 85 downregulated transcripts, using DAVID (B) and KEGG (C) databases. P < 0.05 was used as cutoﬀ for selecting signiﬁcantly enriched biological
pathways.
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lipid metabolism in human adipocytes. However, using standard
1D NMR spectroscopy, the increase in glycerol signals was of
borderline signiﬁcance, and we were unable to diﬀerentiate
between the glycerol linked to phospholipids and the glycerol
linked to triglycerides. Therefore, in order to conﬁrm and reﬁne
the previous results, we measured the triglyceride concentration
using an enzymatic reaction at several stages of human adipocyte
diﬀerentiation and after MEHP treatment (Figure 3).
Intracellular triglyceride accumulation increased linearly dur-
ing the in vitro diﬀerentiation protocol. Eleven days after the
hormonal induction of diﬀerentiation, triglyceride accumulation
reached its maximal level and the cells were then treated with
MEHP. At 24 h, the intracellular triglyceride content was not
aﬀected byMEHP treatment. In contrast, at 48 h, the triglyceride
level was signiﬁcantly higher in MEHP-treated compared to
DMSO-treated adipocytes (213.6( 2.9 μg/mg protein vs. 168.8
( 9.9 μg/mg protein, respectively, p = 0.02, Figure 3). These
results therefore conﬁrmed the increased glycerol signals high-
lighted by 1H NMR after 48 h of MEHP treatment.
Early Effects of MEHP on Human Adipocytes
Transcriptomic and metabonomic results were integrated
using untargeted statistical modeling (Supplemental Figure 2,
Supporting Information). Integration of transcriptomic and
metabonomic data at the same time point (24 h of treatment)
produced poor statistical models, as illustrated by the low
number of p values < 0.1 (p values in blue, Supplemental Figure
2, Supporting Information). In contrast, integration of metabo-
nomic proﬁles obtained at 48 h of treatment and transcriptomic
proﬁles at 24 h produced an overall shift of the p values toward
lower values, indicating stronger associations between these two
data sets (p values in red). This result demonstrated that the
metabolic alterations after 48 h of MEHP treatment correlated
well with the transcriptomic alterations after 24 h, whereas the
metabolic alterations after 24 h of treatment failed to correlate
with the transcriptomic data, suggesting that MEHP may induce
earlier transcriptomic alterations.
To further explore this hypothesis, we performed comple-
mentary transcriptomic experiments at earlier time points and we
assessed the expression of selected genes involved in key
adipocyte metabolic processes (e.g., diﬀerentiation, glyceroneo-
genesis, fatty acid synthesis...) after 4, 8, and 24 h of treatment
with MEHP (Figure 4). At 24 h of treatment with MEHP, most
of the tested genes were signiﬁcantly upregulated, which
Figure 2. 1H NMR-based metabonomic investigation MEHP eﬀects on human adipocytes. (A) Representative 1H NMR spectra (600 MHz) derived
from an aqueous extract of human adipocytes. (B) Plot of O-PLS-DA coeﬃcients related to the discrimination between 1H NMR spectra from aqueous
extracts of human adipocytes treated withMEHP (n = 5, top) vs. DMSO (n = 5, bottom) for 48 h. O-PLS-DA parameters: R2X = 0.65, R2Y = 0.94,Q2Y =
0.73, p = 9 103, one predictive and one orthogonal component. (C) Representative 1H NMR spectra (600 MHz) derived from an organic extract of
human adipocytes. uk: unknown compound. (D) Plot of O-PLS-DA coeﬃcients related to the discrimination between 1H NMR spectra from organic
extracts of human adipocytes treated withMEHP (n = 5, top) vs. DMSO (n = 5, bottom) for 48 h. O-PLS-DA parameters: R2X = 0.93, R2Y = 0.98,Q2Y =
0.68, p = 0.03, one predictive and two orthogonal components. Leu: leucine; Ile: isoleucine; Val: valine; Glu: glutamate; Gln: glutamine; Asp: aspartate;
TMA: trimethylamine; Cre: creatine; PC: phosphocholine; uk: unknown compound; PEA: phosphoethanolamine; NMN: N-methylnicotinamide;
NAD: nicotinamide adenine dinucleotide; Tyr: tyrosine; Phe: phenylalanine.
Figure 3. Intracellular triglycerides in human adipocytes. Human
preadipocytes (n = 5) were diﬀerentiated in vitro into adipocytes for
11 days and then treated with MEHP (100 μM) or DMSO (0.1%,
vehicle) for 24 or 48 h. Black: DMSO, red: MEHP. *: P < 0.05 compared
to DMSO-treated cells, Wilcoxon signed-rank test.
5498 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
Journal of Proteome Research ARTICLE
conﬁrmed the microarray results. On the contrary, at earlier time
points, only two genes were upregulated: the phosphoenolpyr-
uvate carboxykinase 1 (PCK1) and the pyruvate dehydrogenase
kinase 4 (PDK4), which encode the two main enzymes involved
in glyceroneogenesis.23,24
Glyceroneogenesis is a metabolic pathway that converts
glucogenic precursors such as pyruvate or lactate into glycerol-
3-phosphate, which is then used for triglyceride synthesis
(Figure 5A). It has been demonstrated that the cytosolic
phosphoenolpyruvate carboxykinase (PEPCK-C), the protein
encodedby thePCK1gene, is the key enzyme in glyceroneogenesis.25
Therefore, we assessed PEPCK-C protein expression after
MEHP treatment. After 18 h of MEHP treatment, the PEPCK-C
protein content was increased (Figure 5B). Furthermore,
glyceroneogenesis contributes to regulate the release of non-
esteriﬁed fatty acids (NEFA) from WAT in the circulation.25
NEFA release from adipocytes indeed represents a balance
between fatty acid breakdown by lipolysis, and fatty acid
reesteriﬁcation into triglycerides, which are then released into
the bloodstream (Figure 5A). The eﬀects of MEHP on NEFA
reesteriﬁcation were investigated in human adipocytes by eval-
uating NEFA release into the culture medium during fasting. At
18 h of treatment withMEHP orDMSO, human adipocytes were
transferred for 3 h into a glucose-deprived culture medium, in
which the NEFA content was determined. NEFA release was
signiﬁcantly lower in MEHP-treated than in DMSO-treated
adipocytes (75 ( 13 μmol/g protein/h vs 100 ( 12 μmol/g
protein/h respectively, p = 0.03, Figure 5C).
’DISCUSSION
MEHP Enhances the Expression of Genes Associated with
PPARγ Activation in Human Adipocytes Differentiated in
Vitro
This study is the ﬁrst attempt to decipher the eﬀects of the
pollutant MEHP in a human model of WAT. We used an
untargeted combined transcriptomic1H NMR-based metabo-
nomic approach to derive hypotheses about the mechanisms of
action of MEHP, which were then conﬁrmed using targeted
molecular methods. Transcriptomic proﬁling of human adipo-
cytes diﬀerentiated in vitro, established that 24 h of MEHP
treatment signiﬁcantly induced the expression of 12 genes
involved in “PPAR signaling pathway” (p = 3  107, Figure 1,
Supplementary Table 3, Supporting Information). Seven of these
12 genes have a known consensus sequence for PPAR binding
(PPAR response element) in their promoter: PCK1,26 PDK4,27
adipocyte diﬀerentiation related protein (ADRP),28 lipoprotein
lipase (LPL), fatty-acid translocase (CD36), acyl CoA synthetase
1 (ACS1), and adiponectin (AdipoQ).3
In keeping with our ﬁndings, studies in 3T3-L1 preadipocytes
showed that MEHP was a selective PPARγ activator.6 In this
Figure 5. MEHP induced early metabolic alterations in human adipo-
cytes. (A) General description of the glyceroneogenesis and NEFA
reesteriﬁcation pathways in adipocytes (adapted from ref 25). (B)
PEPCK-C protein expression in human adipocytes treated with MEHP
(100 μM) or DMSO (0.1%) for 18 h. Representative Western blot. (C)
NEFA release in the culture medium of human adipocytes treated with
MEHP (100 μM) or DMSO (0.1%) for 18 h and fasted for 3 h. Results
represent a mean ( SEM for three replicates per individual (n = 5). *:
P < 0.05 compared to DMSO-treated cells, Wilcoxon signed-rank test.
Figure 4. MEHP induced early transcriptomic alterations in human
adipocytes. mRNA expression of genes involved in adipocyte diﬀeren-
tiation (A), glycerol metabolism (B), and other lipid-related metabolic
pathways (C) in MEHP-treated (100 μM) or DMSO-treated (0.1%)
human adipocytes. Data represent fold changes compared to DMSO-
treated human adipocytes (mean( SEM, n = 5). *: P < 0.05, **: p < 0.01
compared to DMSO-treated cells, Wilcoxon signed-rank test.
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murine cell line, MEHP induced the selective recruitment of
transcription cofactors by PPARγ, leading to induction of the
expression of a restricted subgroup of genes compared to
treatment with rosiglitazone, a full agonist of PPARγ. For
example, in 3T3-L1 preadipocytes, 10 days of MEHP treatment
induced the expression of adipoQ, CD36, ACS1, LPL, fatty acid
binding protein 4 (FABP4), cAMP element binding protein
alpha (CEBPα), and liver X receptor alpha (LRXα), whereas
rosiglitazone but not MEHP induced the expression of glycerol
kinase (GlyK) and oxidized low density lipoprotein receptor 1
(Olr1). This selective gene activation indicated that MEHP-
induced PPARγ target gene expression depended on the pro-
moter context. This work in 3T3-L1 cells also highlighted the fact
that PPARγ transactivation by MEHP diﬀered according to the
analyzed cell line, which emphasizes the importance of conﬁrm-
ing these results in human cells, where the cellular coregulator
equipment might diﬀer. Using human adipocytes diﬀerentiated
in vitro, we observed a similar gene induction pattern after
MEHP treatment as in 3T3-L1 preadipocytes, i.e., induction of
the expression of FABP4, adipoQ, CD36, ACS1, LPL, CEBPα,
and LRXα genes but not of GlyK or Olr1 genes (Supplementary
Table 2, Supporting Information, Figure 4). However, in pre-
vious studies GlyK and Olr1 were activated by full agonists of
PPARγ in human adipocytes.29,30 Thus, our results showed a
restricted gene induction proﬁle in MEHP-treated human adi-
pocytes compared to full PPARγ agonists, indicating that MEHP
might be a selective PPARγ activator in human adipocytes.
MEHP Has a Pro-Differentiating Effect on Human Adipo-
cytes Differentiated in Vitro
PPARγ is a key regulator of adipogenesis, the process through
which ﬁbroblast-like preadipocytes are converted into mature
adipocytes. In 3T3-L1 murine preadipocytes, MEHP-dependent
PPARγ activation promotes adipogenesis.6 In the present work,
human preadipocytes were ﬁrst diﬀerentiated in vitro for 11 days.
Intracellular triglycerides accumulation, a phenotypic marker of
diﬀerentiation, increased linearly during in vitro diﬀerentiation
(Figure 3). Triglyceride accumulation peaked 11 days after the
hormonal induction of diﬀerentiation, and the cells were then
treated with MEHP for one or two additional days. Although a
large proportion of cells (6070%) were already diﬀerentiated at
this stage, one possibility was the resumption of diﬀerentiation in
the remaining preadipocytes.
Adipocyte diﬀerentiation is a very complex phenomenon that
converts ﬁbroblastic preadipocytes into mature adipocytes. This
process involves dramatic increases in triglyceride content,
drastic morphologic changes, and enhanced transcription of
adipocyte-speciﬁc genes.31 In the present work, MEHP treat-
ment was associated with numerous transcriptomic alterations
conﬁrming that MEHP induced further diﬀerentiation of hu-
mans adipocytes diﬀerentiated in vitro. First, a well-described
hallmark of the adipogenesis process is the dramatic alteration in
cell shape as the cells convert from a ﬁbroblastic to a spherical cell
shape. These morphological modiﬁcations occur simultaneously
with changes in the levels and types of extracellular matrix
components.31 Here, we showed that MEHP treatment for 24 h
disturbed genes linked to “actin cytoskeleton regulation” and
“extracellular matrix” (Figure 1), indicating an eﬀect on cell shape
and on interactions of cells with the extracellular matrix. For
instance, MEHP regulated the expression of two collagen genes
(COL4A6 *1.35, COL8A6 *-1.56, Supplementary Table 2,
Supporting Information). This switch in the expression of
collagen genes is a well-described event in adipogenesis.31
Second, MEHP enhanced the expression of genes involved in
all metabolic pathways leading to triglyceride synthesis and
storage in human adipocytes: channeling and transport of fatty
acids (LPL, CD36, FABPs), production of glycerol-3-phosphate
(glycerol-3P dehydrogenase (G3PDH), PCK1) and of fatty acid-
CoA esters (acylCoA synthase 2 (ACSF2), acylCoA synthase
long chain 3 (ACSL3) and ACSL5), and de novo lipogenesis
(acetylCoA carboxylase (ACCb), fatty acid synthase (FAS))
(Supplementary Table 2, Supporting Information).
In addition to these transcriptomic alterations, metabolic proﬁl-
ing revealed drastic changes in MEHP-treated cells. First, MEHP
increased the signals of protons involved in lipid double bonds, as
well as the aspartate and NAD contents (Figure 2). All these
metabolic changes have been reported previously during the
diﬀerentiation of 3T3-L1 preadipocytes to adipocytes.3234 Indeed,
fatty acid desaturation and aspartate transfer for putrescine synth-
esis were previously shown to be required for 3T3-L1 conversion
into adipocytes.35,36 Second, MEHP decreased the intracellular
concentrations of lactate and glutamine, possibly via increased use
of these substrates for de novo lipogenesis.37,38 Finally, 1H NMR-
based metabolic proﬁling, as well as subsequent enzymatic assays,
demonstrated that after 48 h of treatment,MEHP further increased
the intracellular triglyceride level (Figure 3). Altogether, these
results demonstrate that MEHP had a pro-diﬀerentiating eﬀect
on human adipocytes diﬀerentiated in vitro.
MEHP Activated Glyceroneogenesis and Enhanced NEFA
Reesterification Early in Mature Human Adipocytes
Interestingly, early modulations in the metabolic proﬁles of
MEHP-treated human adipocytes occurred prior to the increase
in intracellular triglycerides. In addition, at 24 h of treatment with
MEHP, untargeted statistical integration of both transcriptomic
and metabonomic proﬁles revealed poor correlations. This result
suggested that MEHP induced early modulation of gene expres-
sion in human adipocytes, independently from the diﬀerentiation
process. This hypothesis was conﬁrmed by the strong and
selective induction of two genes, PCK1 and PDK4, at only 4 h of
treatment with MEHP (Figure 4). PDK4 inhibits the activity of
the pyruvate dehydrogenase complex, which is involved in the
synthesis of acetyl-coA from pyruvate. PDK4 induction therefore
contributes to alter the pyruvate toward oxaloacetate production.
PEPCK-C, the product of PCK1, synthesizes phosphoenolpyr-
uvate from oxaloacetate. Therefore, in WAT, combined activa-
tion of PCK1 and PDK4 genes results in the redistribution of the
pyruvate ﬂux toward glyceroneogenesis.24 As previously discussed,
glyceroneogenesis is a metabolic pathway enhanced during fasting
that converts glucogenic precursors such as pyruvate, lactate, or
amino acids into glycerol-3-phosphate, which is subsequently used
for triglyceride synthesis (Figure 5A). Here, glyceroneogenesis
activation by MEHP in human adipocytes was further conﬁrmed
by the observation thatMEHP increased PEPCK-C protein levels.
Since PEPCK-C activity correlates directly with its expression
level,39,40 this observation reﬂected an increased glyceroneogenic
ﬂux in MEHP-treated human adipocytes.
Furthermore, glyceroneogenesis contributes to regulate NEFA
release from WAT to the circulation. NEFA release from adipo-
cytes results from a balance between fatty acid breakdown by
lipolysis and fatty acid reesteriﬁcation into triglycerides, which are
then released into the bloodstream. Fatty acid reesteriﬁcation
accounts for a large proportion of lipolytically derived NEFA
(3070%) and therefore requires glycerol-3- phosphate synthesis,
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which under fasting conditions originates from glyceroneogenesis
(Figure 5A). In the present work, we demonstrated that NEFA
release was reduced in MEHP-treated adipocytes after fasting.
This change might also result from a decrease in lipolysis or β-
oxidation. However, at early time points, we found no decreases in
the expression of genes involved in lipolysis, such as the adipocyte
triglyceride lipase (ATGL) or the hormone-sensitive lipase
(HSL), or in β-oxidation, such as the carnitine palmitoyl transfer-
ase 1 (CPT1). Similarly, a recent study showed no eﬀect of DEHP
on lipolysis in rat adipose tissue.41 Altogether, our results indicate
that more NEFA were reesteriﬁed into triglycerides under MEHP
treatment, for which glycerol backbone was provided by the
concomitant enhancement of glyceroneogenesis.
Finally, it has been demonstrated that PEPCK-C was
expressed only in mature adipocytes and that PPARγ was unable
to activate PCK1 in preadipocytes.42 Therefore, we conclude that
PCK1 induction and the subsequent increases in glyceroneogen-
esis and NEFA reesteriﬁcation observed in human adipocytes
diﬀerentiated in vitro after MEHP treatment occurred in the
mature adipocytes present in the cell culture.
MEHP Exposure and Expected Consequences for Humans
Although the human exposure to DEHP is ubiquitous, plasma
levels of DEHP and MEHP are thought to remain generally low
because of rapid urinary excretion.43 Plasmatic concentrations of
38 mg/L (∼100 μM) DEHP and of about 1.37 μg/mL (∼3 μM)
MEHP have been measured in healthy individuals.44,45 However,
several parameters such as daily use of cosmetics, mouthing
behavior in children, neonatal intensive care, frequent blood
transfusion or dialysis can increase phthalate exposure 414-fold
compared to control populations.4648 Furthermore, DEHP is a
lipophilic compound that can accumulate in WAT.44 We found no
data on MEHP accumulation in WAT. However, exposure data
suggest that, under certain circumstances, MEHP levels in plasma
and WAT may reach 100 μM, the concentration for which we
observedmetabolic eﬀects in human preadipocytes and adipocytes.
In this work, we have shown thatMEHP increased the triglyceride
content in human adipocytes diﬀerentiated in vitro, which may
be explained by, at least, two concomitant mechanisms: an early
increase in glyceroneogenesis and NEFA reesteriﬁcation occur-
ring in mature adipocytes, followed by diﬀerentiation of the
remaining preadipocytes. In previous studies, both mechanisms
were activated in animal and human WAT by other PPARγ
agonists, such as the antidiabetic drugs thiazolidinediones.22,49
Both mechanisms contribute to the global improvement in
carbohydrate and lipid homeostasis observed during thiazolidi-
nedione treatment. However, they also both result in increased
triglyceride accumulation in WAT and are thought to participate
in the weight-gain promoting eﬀect of these drugs. These
mechanisms may thus contribute to the suspected obesogen
eﬀect of MEHP and of other phthalates capable of activating
PPARγ. Epidemiological studies have indeed shown a positive
correlation between urinary MEHP concentrations and waist
circumference in healthy men50 and between other phthalate
metabolites and body mass index.51
In addition, glyceroneogenesis activation by MEHP may also
interfere more generally with energy homeostasis in exposed
populations. The eﬀect of PEPCK-C in WAT on both glycer-
oneogenesis and reesteriﬁcation of NEFA to triglycerides is
crucial to prevent diabetes. PEPCK-C dysregulation interferes
with the triglyceride/fatty acid cycle, which regulates lipid
synthesis and transport between WAT and the liver, leading to
the development of insulin resistance in mice.52 In another study,
Franckhauser et al. demonstrated that transgenic mice overexpres-
sing PEPCK-C inWAT remained insulin sensitive under a high-fat
diet but developed severe obesity and weremore hyperinsulinemic,
glucose intolerant, and insulin resistant than wild-type controls.53
Thus, PEPCK-C overexpression in adipose tissue increased the
susceptibility to diet-induced obesity and insulin resistance. These
results, together with our present work, suggest that phthalate
exposure might be of particular concern in populations already
susceptible to insulin resistance because of an unbalanced diet.
’CONCLUSION
This study in a humanWATmodel provides the ﬁrst evidence
that the environmental pollutant MEHP promotes triglyceride
storage by altering the metabolism of both preadipocytes and
mature adipocytes. The earliest eﬀects of MEHP were increases
in glyceroneogenesis and NEFA reesteriﬁcation in mature adi-
pocytes, which interfered with the regulation of fatty acid release
by humanWAT. After a longer treatment time,MEHP had a pro-
diﬀerentiating eﬀect on the preadipocytes remaining in the cell
cultures. These results provide convincing new evidence that
MEHP interferes with endogenous lipid metabolism in human
WAT and should therefore be considered as a potential obeso-
gen, as well as a more general metabolic disruptor.
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